Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells

Pharmaceutical Research

Volumn 31, Issue 9, 2014, Pages 2439-2452

  Youm, Ibrahima ^a   Agrahari, Vivek ^a   Murowchick, James B ^a   Youan, Bi Botti C ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

breast cancer; cancer chemotherapy; CD44 receptor; cytotoxicity; hyaluronic acid; nanocapsules; particle cellular uptake

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; HYALURONIC ACID; NANOCAPSULE; REACTIVE OXYGEN METABOLITE; TAXOID;

3T3 CELL LINE; ANIMAL; BREAST; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; HYALURONIC ACID; MICE; NANOCAPSULES; NIH 3T3 CELLS; REACTIVE OXYGEN SPECIES; TAXOIDS;

EID: 84896412005     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1339-x     Document Type: Article

References (39)

1. Berezhnoy A, Brenneman R, Bajgelman M, Seales D, Gilboa E. Thermal stability of siRNA modulates aptamer- conjugated siRNA inhibition. Mol Ther Nucleic Acids. 2012;1:e51.
2. Oh Y-K, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61(10):850-62.
3. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377-80.
4. Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, Ye M, et al. A novel aptamer developed for breast cancer cell internalization. Chem Med Chem. 2012;7(1):79-84.
5. Jin YJ, Termsarasab U, Ko SH, Shim J-S, Chong S, Chung S-J, et al. Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma. Pharm Res. 2012;29(12):3443-54.
6. Tsai SW, Fang JF, Yang CL, Chen JH, Su LT, Jan SH. Preparation and evaluation of a hyaluronate-collagen film for preventing post-surgical adhesion. J Int Med Res. 2005;33(1):68-76.
7. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res. 2005;65(15):6755-63.
8. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241-319.
9. Ahrens T, Sleeman JP, Schempp CM, Howells N, Hofmann M, Ponta H, et al. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene. 2001;20(26):3399-408.
10. de la Torre M, Heldin P, Bergh J. Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers. Anticancer Res. 1995;15(6B):2791-5.
11. Bourguignon LYW, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor β receptor I in metastatic breast tumor cells. J Biol Chem. 2002;277(42):39703-12.
12. Ma Y, Zeng Y, Zeng X, Jiang L, Cheng H, Liu R, et al. Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment. Int J Nanomedicine. 2011;6:2679-88.
13. Ren S-T, Liao Y-R, Kang X-N, Li Y-P, Zhang H, Ai H, et al. The antitumor effect of a new docetaxel-loaded microbubble combined with low-frequency ultrasound in vitro: preparation and parameter analysis. Pharm Res. 2013;30(6):1574-85.
14. Huynh N, Morille M, Bejaud J, Legras P, Vessieres A, Jaouen G, et al. Treatment of 9 L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect. Pharm Res. 2011;28(12):3189-98.
15. Box GEP, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics. 1960;2(4):455-75.
16. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol. 2010;624:163-75.
17. Quintanar-Guerrero D, Allémann E, Doelker E, Fessi H. Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique. Pharm Res. 1998;15(7):1056-62.
18. Youm I, Murowchick JB, Youan BBC. Entrapment and release kinetics of furosemide from pegylated nanocarriers. Colloids Surf B: Biointerfaces. 2012;94(1):133-42.
19. Hackley V, Ferraris C. The use of nomenclature in dispersion science and technology. SP: NIST Recommended Practice Guide; 2001.
20. Venishetty VK, Parikh N, Sistla R, Ahmed FJ, Diwan PV. Application of validated RP-HPLC method for simultaneous determination of docetaxel and ketoconazole in solid lipid nanoparticles. J Chromatogr Sci. 2011;49(2):136-41.
21. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-33.
22. Haugland R. Handbook of fluorescent probes and research chemicals. 6 ed. Eugene: Molecular Probes; 1996.
23. Kaur P, Aschner M, Syversen T. Glutathione modulation influences methyl mercury induced neurotoxicity in primary cell cultures of neurons and astrocytes. Neurotoxicology. 2006;27(4):492-500.
24. Yetilmezsoy K, Demirel S, Vanderbei RJ. Response surface modeling of Pb(II) removal from aqueous solution by pistacia vera L.: box-behnken experimental design. J Hazard Mater. 2009;171(1-3):551-62.
25. Liu Y, Sun J, Cao W, Yang J, Lian H, Li X, et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm. 2011;421(1):160-9.
26. Zaske L, Perrin MA, Leveiller F. Docetaxel: solid state characterization by X-ray powder diffraction and thermogravimetry. J Phys IVFrance 11. 2001.
27. Youm I, Yang X, Murowchick J, Youan BBC. Encapsulation of docetaxel in oily core polyester nanocapsules intended for breast cancer therapy. Nanoscale Res Lett. 2011;6(1):630.
28. Abdelwahed W, Degobert G, Fessi H. A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. Int J Pharm. 2006;309(1-2):178-88.
29. Na DH, DeLuca PP. PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by Poly(D, L-lactide-co-glycolide). Pharm Res. 2005;22(5):736-42.
30. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73(2-3):121-36.
31. Luo Y, Ling Y, Guo W, Pang J, Liu W, Fang Y, et al. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release. 2010;147(2):278-88.
32. Lai MK, Chang CY, Lien YW, Tsiang RC. Application of gold nanoparticles to microencapsulation of thioridazine. J Control Release. 2006;111(3):352-61.
33. Platt VM, Szoka FC. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan Receptor. Mol Pharm. 2008;5(4):474-86.
34. Karihtala P, Soini Y, Auvinen P, Tammi R, Tammi M, Kosma V-M. Hyaluronan in breast cancer: correlations with nitric oxide synthases and tyrosine nitrosylation. J Histochem Cytochem. 2007;55(12):1191-8.
35. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387-400.
36. Sheridan C, Kishimoto H, Fuchs R, Mehrotra S, Bhat-Nakshatri P, Turner C, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8(5):R59.
37. Choi KY, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials. 2011;32(7):1880-9.
38. Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol. 1993;122(1):257-64.
39. Qhattal S, Liu X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm. 2011;8(4):1233-46.